NEW YORK – Finnish molecular diagnostics company Mobidiag announced Tuesday that it has been granted €1.5 million ($1.68 million) in funding from Business Finland to advance a sepsis test on the firm's Novodiag system.
Business Finland — a government agency which funds research in the country — awarded Mobidiag an initial grant in 2018, and the new funding brings the total amount awarded to $3.3 million.